Calquence Improves Survival in Relapsed Chronic Lymphocytic Leukemia

An interim analyses of the phase 3 ASCEND clinical trial evaluating single-agent Calquence acalabrutinib compared to Rituxan rituximab plus idelasib or bendamustine in recurrent chronic lymphocytic leukemia CLL is closed early due to favorable results 1 A [...]